Cross-Species Organ Transplantation Market Report 2026

Cross-Species Organ Transplantation Market Overview

• Cross-Species Organ Transplantation market size has reached to $15.2 billion in 2025 • Expected to grow to $22.65 billion in 2030 at a compound annual growth rate (CAGR) of 8.2% • Growth Driver: Surge In Organ Failure Fueling The Growth Of The Market Due To Rising Trauma Related Multiple Organ Failure • Market Trend: Strategic Partnerships Accelerating Clinical Trials For Xenotransplantation • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cross-Species Organ Transplantation Market?

Cross-species organ transplantation, also known as xenotransplantation, is the transplantation of living cells, tissues, or whole organs from one species into a different species, typically from animals to humans. The primary goal of xenotransplantation is to address the shortage of human donor organs for patients in need of transplants The main product types of cross-species organ transplantation are organ preservation solution, transplant diagnostics, xeno products, and others. Organ preservation solution is a specially formulated liquid used to keep organs viable outside the body during transportation and before transplantation. It is applied in various applications, including kidney, heart, liver, lung, and others, and is used by several end users, including transplant centers, hospitals, and others.

What Is The Cross-Species Organ Transplantation Market Growth Forecast?

The cross-species organ transplantation market size is expected to see strong growth in the next few years. It will grow to $22.65 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to increasing clinical trial activity in xenotransplantation, rising investment in gene-edited animal models, growing collaboration between biotech firms and transplant centers, advancements in immunosuppressive therapies, expanding regulatory frameworks for xenotransplants. Major trends in the forecast period include increasing advancements in genetically engineered donor organs, growing focus on immune rejection mitigation strategies, expansion of organ preservation and perfusion technologies, rising investment in translational xenotransplant research, enhanced regulatory and ethical oversight.

What Is The Driver Of The Cross-Species Organ Transplantation Market?

The growing shift towards genetic engineering is expected to propel the growth of the cross-species organ transplantation market going forward. Genetic engineering refers to the deliberate modification of an organism’s DNA using biotechnology techniques to introduce, remove, or alter specific genes. The rise in genetic engineering is due to the urgent need to address organ shortages by creating animal organs that are more compatible for human transplantation. Genetic engineering supports the growth of cross-species organ transplantation by enabling the modification of animal organs to reduce immune rejection, making them suitable for human transplants. For instance, in July 2023, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based non-profit medical and scientific organization, there were 247 gene therapies in Phase II by the end of first quarter of 2023, increasing by 5% to reach 260 by the end of the second quarter. Therefore, the growing shift towards genetic engineering is driving the growth of the cross-species organ transplantation industry.

Key Players In The Global Cross-Species Organ Transplantation Market

Major companies operating in the cross-species organ transplantation market are Novartis AG, Optipharm Co Ltd, Astellas Pharma Inc., United Therapeutics Corporation, TransMedics Group Inc., Artivion Inc., eGenesis Inc., Organ Recovery Systems Inc., OrganOX Ltd, Paragonix Technologies Inc., Qihan Biotech, PorMedTec Co., XenoTheraputics Inc., Makana Therapeutics Inc., Preservation Solutions Inc., Nzeno Ltd, Infigen Inc., Revivicor Inc., XVIVO Perfusion AB, Bridge To Life Ltd, Transplant Genomics Inc.

Global Cross-Species Organ Transplantation Market Trends and Insights

Major companies operating in the cross-species organ transplantation market are focusing on adopting strategic partnerships to streamline the regulatory approval process for xenotransplantation solutions. A strategic partnership is an alliance where companies work together to achieve common goals by utilizing each other’s strengths and resources, aiming to boost growth, innovation, and competitiveness without merging. For instance, in February 2025, United Therapeutics, a US-based biotechnology company, and eGenesis, a US-based pharmaceutical company to begin clinical trials for pig kidney (xenotransplant) transplants in humans. This trial received approval from the U.S. Food and Drug Administration (FDA) to transplant genetically modified pig kidneys into patients with kidney failure. The trials aim to address the critical shortage of donor kidneys by potentially providing a new, sustainable organ source for those in need.

What Are Latest Mergers And Acquisitions In The Cross-Species Organ Transplantation Market?

In December 2023, United Therapeutics Corporation, a US-based biotechnology company that provides xenotransplantation solutions, acquired Miromatrix Medical Inc. for an undisclosed amount. With this acquisition, United Therapeutics Corporation expanded its capabilities in developing bioengineered organs for transplantation, particularly in advancing its cross-species (xenotransplantation) initiatives. Miromatrix Medical Inc. is a US-based company that provides bioengineered organs derived through decellularization and recellularization techniques.

What Defines the Cross-Species Organ Transplantation Market?

The cross-species organ transplantation market consists of revenues earned by entities by providing services such as preclinical and clinical xenotransplantation services, organ and tissue matching, post-transplant care and monitoring, and regenerative and bioengineered solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The cross-species organ transplantation market also includes sales of immunosuppressive drugs, bioengineered tissues, and organ scaffolds or matrices. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cross-Species Organ Transplantation Market Report 2026?

The cross-species organ transplantation market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cross-species organ transplantation industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.